Masashi Sakayori

Masashi Sakayori

Auto-generated profile, based on publicly available information

Masashi Sakayori

Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6-16-1 Tomioka-higashi, Kanazawa-Ku, Yokohama, 236-0051, Japan

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
MSMasashi Sakayori
Masashi Sakayori
JTJiro Terada
Jiro Terada
MAMitsuhiro Abe
Mitsuhiro Abe
YHYasutaka Hirasawa
Yasutaka Hirasawa
KSKenichi Suzuki
Kenichi Suzuki
KTKoichiro Tatsumi
Koichiro Tatsumi
Although pirfenidone (PFD) is a key drug for the treatment of idiopathic pulmonary fibrosis (IPF), differences in tolerability between elderly and young patients remain unclear. This study aimed to investigate age-related differences in adverse drug reactions to PFD and to evaluate whether patient age influences the safety and tolerability of PFD in clinical practice. One hundred fifty-four patients with IPF were treated with PFD in our institution between May 2009 and April 2017; these patients were classified into 2 groups on the basis of age: ≥75 years of age (elderly patients) and <75 years of age (younger patients). In each group, the clinical course, laboratory data, radiographic findings, adverse events, and tolerability of PFD at 6 months and 1 year after administration were retrospectively analyzed. Among the 120 patients examined in this study, 31 patients (26%) were ≥75 years of age. The continuation rate of PFD at 1 year in the elderly patient group was significantly lower (n=11 [35%] vs 57 [64%], p=0.007) than in the younger patient group. Regarding adverse drug reactions to PFD, the incidence of gastrointestinal disorders including anorexia (n=24 [77%] vs 40 [45%], p=0.002) and the discontinuation caused by gastrointestinal disorders (n=11 [35%] vs 13 [15%], p=0.019) were significantly higher in elderly patients than those in younger patients. However, with the exception of gastrointestinal disorders, other adverse drug reactions did not significantly differ between elderly and younger patients. Compared with younger patients, elderly patients with IPF had a higher incidence of gastrointestinal disorders, along with an increased discontinuation rate of PFD. More careful management of gastrointestinal disorders may be required to ensure continuation of PFD in elderly patients.

13 September 2022 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
MSMasashi Sakayori
Masashi Sakayori
EHEri Hagiwara
Eri Hagiwara
TBTomohisa Baba
Tomohisa Baba
HKHideya Kitamura
Hideya Kitamura
ASAkimasa Sekine
Akimasa Sekine
TOTakashi Ogura
Takashi Ogura

27 September 2021 in Respiratory Medicine Case Reports
Verified
Journal Article
Open access
SSShunya Shiohira
Shunya Shiohira
MSMasashi Sakayori
Masashi Sakayori
KYKeiichiro Yoshioka
Keiichiro Yoshioka
HKHajime Kasai
Hajime Kasai
RHRyutaro Hirama
Ryutaro Hirama
TSTakuji Suzuki
Takuji Suzuki
Herein, we present the case of a 63-year-old man with autoimmune pulmonary alveolar proteinosis (APAP) complicated by Mycobacterium avium complex (MAC) infection. APAP was diagnosed based on serum anti-granulocyte-macrophage colony-stimulating factor antibody, bronchoalveolar lavage fluid (BALF) findings, and transbronchial lung biopsy. Nodular shadows with cavities were visible on chest CT images, and Mycobacterium intracellulare was identified by BALF culture. Rifampicin, ethambutol, and clarithromycin were administered, and 4 months later, the nodular shadows of MAC had disappeared, and APAP was remarkably improved. Thus, in cases of APAP exacerbation complicated with infections, such as MAC, control of the infections may improve APAP.